HLA-G expression in malignant melanoma

Seminars in Cancer Biology

Volumn 17, Issue 6, 2007, Pages 422-429

  Rebmann, Vera ^a   Wagner, Stefan ^b   Grosse Wilde, Hans ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

HLA class I loss; HLA G; ILT 2; Malignant melanoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; GAMMA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA G ANTIGEN; INTERLEUKIN 10; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN PRESENTING CELL; ANTIGEN STRUCTURE; CANCER LOCALIZATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURFACE; COMPARATIVE STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; IMMUNITY; IMMUNOSURVEILLANCE; MELANOMA; NATURAL KILLER CELL; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR CELL; UPREGULATION;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOLOGIC SURVEILLANCE; MELANOMA; SKIN NEOPLASMS; TUMOR ESCAPE;

EID: 35748941628     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2007.06.010     Document Type: Review

References (59)

1. Romero P., Pannetier C., Herman J., Jongeneel C.V., Cerottini J.C., and Coulie P.G. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen. Exp Med 182 (1995) 1019-1028
2. Maeurer M.J., Martin D., Elder E., Storkus W.J., and Lotze M.T. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis. Clin Cancer Res 2 (1996) 87-95
3. Rosenberg S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10 (1999) 281-287 [review]
4. Pilla L., Valenti R., Marrari A., Patuzzo R., Santinami M., Parmiani G., et al. Vaccination: role in metastatic melanoma. Expert Rev Anticancer Ther 6 (2006) 1305-1318 [review]
5. Ferrone S., and Marincola F.M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16 (1995) 487-494
6. Garrido F., Ruiz-Caballo F., Cabrera T., PeÂrez-Villar J.J., Lopez-Botet M., Duggan-Keen M., et al. Implications for immunosurveillance of altered HLA-class I phenotypes in human tumors. Immunol Today 18 (1997) 89-95
7. Geertsen R., Hofbauer G., Yue F.-Y., Burg G., and Dummer R. Higher frequency of selective losses of HLA-A and -B allospecicities in metastases than in primary melanoma lesions. J Invest Dermatol 111 (1998) 497-502
8. Marincola F.M., Shamamian P., Alexander R.B., et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 153 (1994) 1225-1237
9. Paul P., Rouas-Freiss N., Khalil-Daher I., Moreau P., Riteau B., Le Gal F.A., et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 95 (1998) 4510-4515
10. Ibrahim E.C., Guerra N., Lacombe M.J., Angevin E., Chouaib S., Carosella E.D., et al. Tumor-specific upregulation of the nonclassical class I HLA-G antigen expression in renal arcinoma. Cancer Res 61 (2001) 6838-6845
11. Bukur J., Rebmann V., Grosse-Wilde H., Luboldt H., Rübben H., Drexler I., et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 63 (2003) 4107-4111
12. Lefebvre S., Antoine M., Uzan S., McMaster M., Dausset J., Carosella E.D., et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 196 (2002) 266-274
13. Wiendl H., Mitsdoerffer M., Hofmeister V., Wischhusen J., Bornemann A., Meyermann R., et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 168 (2002) 4772-4780
14. Urosevic M., Kurrer M.O., Kamarashev J., Mueller B., Weder W., Burg G., et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 159 (2001) 817-824
15. Urosevic M., Willers J., Mueller B., Kempf W., Burg G., and Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 99 (2002) 609-617
16. Nückel H., Rebmann V., Dürig J., Dührsen U., and Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 105 (2005) 1694-1698
17. Kleinberg L., Florenes V.A., Skrede M., Dong H.P., Nielsen S., McMaster M.T., et al. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch 449 (2006) 31-39
18. Paul P., Cabestre F.A., Ibrahim E.C., Lefebvre S., Khalil-Daher I., Vazeux G., et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol 61 (2000) 1138-1149
19. Diehl M., Munz C., Keilholz W., Stevanovic S., Holmes N., Loke Y.W., et al. Nonclassical HLA-G molecules are classical peptide presenters. Curr Biol 6 (1996) 305-314
20. Shiroishi M., Kuroki K., Ose T., Rasubala L., Shiratori I., Arase H., et al. Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem 281 (2006) 10439-10447
21. Clements C.S., Kjer-Nielsen L., Kostenko L., Hoare H.L., Dunstone M.A., Moses E., et al. Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc Natl Acad Sci USA 102 (2005) 3360-3365
22. Boyson J.E., Erskine R., Whitman M.C., Chiu M., Lau J.M., Koopman L.A., et al. Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci USA 99 (2002) 16180-16185
23. Arnaiz-Villena A., Martinez-Laso J., Serrano-Vela J.I., Reguera R., and Moscoso J. HLA-G polymorphism and evolution. Tissue Antigen 69 (2007) 156-159
24. Rouas-Freiss N., Marchal R.E., Kirszenbaum M., Dausset J., and Carosella E.D. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?. Proc Natl Acad Sci USA 94 (1994) 5249-5255
25. Le Gal F.A., Riteau B., Sedlik C., et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 11 (1999) 1351-1356
26. Le Rond S., Azema C., Krawice-Radanne I., et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T Cells. J Immunol 176 (2006) 3266-3276
27. LeMaoult J., Krawice-Radanne I., Dausset J., and Carosella E.D. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD41 T cells. Proc Natl Acad Sci USA 101 (2004) 7064-7069
28. Horuzsko A., Lenfant F., Munn D.H., and Mellor A.L. Maturation of antigen-presenting cells is compromised in HLA-G transgenic mice. Int Immunol 13 (2001) 385-394
29. Ristich V., Liang S., Zhang W., Wu J., and Horuzsko A. Tolerization of dendritic cells by HLA-G. Eur J Immunol 35 (2005) 1133-1134
30. Kanai T., Fujii T., Kozuma S., Yamashita T., Miki A., Kikuchi A., et al. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. Mol Hum Reprod 7 (2001) 195-200
31. Rieger L., Hofmeister V., Probe C., Dietl J., Weiss E.H., Steck T., et al. Th1- and Th2-like cytokine production by first trimester decidual large granular lymphocytes is influenced by HLA-G and HLA-E. Mol Hum Reprod 8 (2002) 255-261
32. Lila N., Rouas-Freiss N., Dausset J., Carpentier A., and Carosella E.D. Soluble HLA-G protein secreted by allo-specific CD4 T cells suppresses the allo-proliferative response: a CD4 T cell regulatory mechanism. Proc Natl Acad Sci USA 98 (2001) 12150-12155
33. Contini P., Ghio M., Poggi A., Filaci G., Indiveri F., Ferrone S., et al. Soluble HLA-A,-B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 33 (2003) 125-134
34. Sanders S.K., Giblin P.A., and Kavathas P. Cell-cell adhesion mediated by CD8 and human histocompatibility leukocyte antigen G, a nonclassical major histocompatibility complex class 1 molecule on cytotrophoblasts. J Exp Med 174 (1991) 737-740
35. Witt C.S., Whiteway J.M., Warren H.S., Barden A., Rogers M., Martin A., et al. Alleles of the KIR2DL4 receptor and their lack of association with pre-eclampsia. Eur J Immunol 32 (2002) 18-29
36. Riteau B., Menier C., Khalil-Daher I., Martinozzi S., Pla M., Dausset J., et al. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol 13 (2001) 193-201
37. Colonna M., Navarro F., Bellon T., Llano M., Garcia P., Samaridis J., et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 186 (1997) 1809-1818
38. Naji A., Durrbach A., Carosella E.D., and Rouas-Freiss N. Soluble HLA-G and HLA-G1 expressing antigen-presenting cells inhibit T-cell alloproliferation through ILT-2/ILT-4/FasL-mediated pathways. Hum Immunol 68 (2007) 233-239
39. LeMaoult J., Zafaranloo K., Le Danff C., and Carosella E.D. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 19 (2005) 662-664
40. Urosevic M., Trojan A., and Dummer R. HLA-G and its KIR ligands in cancer-another enigma yet to be solved?. J Pathol 196 (2002) 252-253 [review]
41. Chang C.C., Murphy S.P., and Ferrone S. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. Hum Immunol 64 (2003) 1057-1063 [review]
42. Polakova K., and Russ G. Expression of the non-classical HLA-G antigen in tumor cell lines is extremely restricted. Neoplasma 47 (2000) 342-348
43. Rouas-Freiss N., Bruel S., Menier C., Marcou C., Moreau P., and Carosella E.D. Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis. Int J Cancer 117 (2005) 114-122
44. Anastassiou G., Rebmann V., Wagner S., Bornfeld N., and Grosse-Wilde H. Expression of classic and nonclassic HLA class I antigens in uveal melanoma. Invest Ophthalmol Vis Sci 44 (2003) 2016-2019
45. Gobin S.J., Keijsers V., van Zutphen M., and van den Elsen P.J. The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor kappa B. J Immunol 161 (1998) 2276-2283
46. Rodriguez T., Mendez R., Del Campo A., Jimenez P., Aptsiauri N., Garrido F., et al. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 7 (2007) 34
47. Algarra I., Gaforio J.J., Cabrera T., Collado A., and Garrido F. The biological consequences of altered MHC class I expression in tumors. J Biol Regul Homeost Agents 13 (1999) 90-96 [review]
48. Elsner H.A., Drabek J., Rebmann V., Ambruzova Z., Grosse-Wilde H., and Blasczyk R. Non-expression of HLA-B*5111N is caused by an insertion into the cytosine island at exon 4 creating a frameshift stop codon. Tissue Antigens 57 (2001) 369-372
49. Elsner H.A., Bernard G., Eiz-Vesper B., de Matteis M., Bernard A., and Blasczyk R. Nonexpression of HLA-A*2901102 N is caused by a nucleotide exchange in the mRNA splicing site at the beginning of intron 4. Tissue Antigens 59 (2002) 139-141
50. Seliger B., Ritz U., Abele R., Bock M., Tampe R., Sutter G., et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 61 (2001) 8647-8650
51. Fernandez M.A., Ruiz-Cabello F., Oliva M.R., Cabrera T., Jimenez P., Lopez Nevot M.A., et al. Beta2-microglobulin gene mutation is not a common mechanism of HLA class I total loss in human tumors. Int J Clin Lab Res 30 (2000) 87-92
52. Willers J., Urosevic M., Laine E., Geertsen R., Kundig T., Burg G., et al. Decreased intraindividual HLA class I expression is due to reduced transcription in advanced melanoma and does not correlate with HLA-G expression. J Invest Dermatol 117 (2001) 1498-1504
53. Moreau P., Adrian-Cabestre F., Menier C., Guiard V., Gourand L., Dausset J., et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 11 (1999) 803-811
54. Ugurel S., Rebmann V., Ferrone S., Tilgen W., Grosse-Wilde H., and Reinhold U. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 92 (2001) 369-376
55. Lefebvre S., Berrih-Aknin S., Adrian F., Moreau P., Poea S., Gourand L., et al. A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J Biol Chem 276 (2001) 6133-6139
56. Wagner S.N., Rebmann V., Willers C.P., Grosse-Wilde H., and Goos M. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet 356 (2000) 220-221
57. Moreau P., Mouillot G., Rousseau P., Marcou C., Dausset J., and Carosella E.D. HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci USA 100 (2003) 1191-1196
58. Yan W.H., Lin A.F., Chang C.C., and Ferrone S. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2′-deoxycytidine. Cell Res 15 (2005) 523-531
59. Lonchay C., van der Bruggen P., Connerotte T., Hanagiri T., Coulie P., Colau D., et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 101 Suppl. 2 (2004) 14631-14638